secwatch.observer — SEC 8-K summary
======================================

Issuer:     Propanc Biopharma, Inc. (PPCB)
CIK:        0001517681
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001493152-22-030113
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Propanc Biopharma enters amended employment agreement with CEO James Nathanielsz
--------------------------------------------------------------------------------

- New base salary of $600,000 AUD per annum, plus salary sacrifice for tuition up to $200,000 AUD.
- Annual discretionary bonus reduced to up to 100% of base salary (from 200% previously).
- Term of 3 years from July 1, 2022, with automatic yearly renewal unless terminated.
- Severance: one year's base salary upon termination without cause or company non-renewal; only accrued amounts if executive non-renewal.
- Includes one-year non-compete and indemnification provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517681/000149315222030113/0001493152-22-030113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517681/000149315222030113/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer